UA99729C2 - Heteroaryl amide analogues - Google Patents
Heteroaryl amide analoguesInfo
- Publication number
- UA99729C2 UA99729C2 UAA200913336A UAA200913336A UA99729C2 UA 99729 C2 UA99729 C2 UA 99729C2 UA A200913336 A UAA200913336 A UA A200913336A UA A200913336 A UAA200913336 A UA A200913336A UA 99729 C2 UA99729 C2 UA 99729C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heteroaryl amide
- disorder
- amide analogues
- analogues
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula la and/or Ib. In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2Xreceptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95525007P | 2007-08-10 | 2007-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA99729C2 true UA99729C2 (en) | 2012-09-25 |
Family
ID=40351102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200913336A UA99729C2 (en) | 2007-08-10 | 2008-08-11 | Heteroaryl amide analogues |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2185560A4 (en) |
JP (2) | JP2010535816A (en) |
KR (1) | KR20100066422A (en) |
CN (1) | CN101778850A (en) |
AU (1) | AU2008286946B2 (en) |
BR (1) | BRPI0812594A2 (en) |
CA (1) | CA2691512A1 (en) |
CO (1) | CO6251319A2 (en) |
EA (1) | EA020332B1 (en) |
IL (1) | IL202550A0 (en) |
NZ (1) | NZ582056A (en) |
SG (1) | SG183699A1 (en) |
UA (1) | UA99729C2 (en) |
WO (1) | WO2009023623A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010237302A1 (en) * | 2009-04-14 | 2011-12-01 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
WO2012110190A1 (en) * | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
CN103635230B (en) | 2011-05-12 | 2017-10-31 | 普罗蒂斯特斯治疗公司 | Albumen homeostasis conditioning agent |
WO2012163792A1 (en) * | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) * | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
ES2574840T3 (en) | 2011-07-22 | 2016-06-22 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as antagonists of p2x7 receptors |
EP2804865B1 (en) * | 2012-01-20 | 2015-12-23 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
JOP20130213B1 (en) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | 5-ht3 receptor antagonists |
BR112015013463B1 (en) | 2012-12-12 | 2022-06-14 | Idorsia Pharmaceuticals Ltd | CARBOXAMIDE INDOL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS |
AR094053A1 (en) | 2012-12-18 | 2015-07-08 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF INDOL CARBOXAMIDE AS ANTAGONISTS OF THE P2X RECEIVER |
ES2616114T3 (en) | 2013-01-22 | 2017-06-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
CA2897459C (en) * | 2013-01-22 | 2021-03-02 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
PE20151332A1 (en) | 2013-02-19 | 2015-09-20 | Pfizer | AZABENZIMIDAZOLE COMPOUNDS |
JO3509B1 (en) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | P2x7 modulators |
JO3773B1 (en) * | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | P2x7 modulators |
US9096596B2 (en) | 2013-03-14 | 2015-08-04 | Janssen Pharmaceutica Nv | P2X7 modulators |
US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
CN105636646B (en) * | 2013-07-17 | 2017-12-19 | 全球结核病药物研发联盟 | Azaindole compounds, its synthesis and its application method |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
CN106795165B (en) | 2014-08-06 | 2019-09-10 | 辉瑞公司 | Imidazopyridazine compounds |
JP6592510B2 (en) | 2014-09-12 | 2019-10-16 | ヤンセン ファーマシューティカ エヌ.ベー. | P2X7 regulator |
ES2883295T3 (en) | 2014-09-29 | 2021-12-07 | Takeda Pharmaceuticals Co | Crystalline form of 1- (1-methyl-1h-pyrazol-4-yl) -n - ((1r, 5s, 7s) -9-methyl-3-oxa-9-azabicyclo [3.3.1] nonan-7- yl) -1h-indole-3-carboxamide |
US10323000B2 (en) | 2014-12-15 | 2019-06-18 | Merck Patent Gmbh | Indole derivatives and their use in neurodegenerative diseases |
JP6462493B2 (en) | 2015-05-29 | 2019-01-30 | 株式会社デンソー | Approach determination device, approach determination method |
US20190016680A1 (en) | 2016-01-14 | 2019-01-17 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
TW201819361A (en) | 2016-09-03 | 2018-06-01 | 印度商托仁特生技有限公司 | Novel indazole compounds |
US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
EP3856178A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
EP4038070A1 (en) | 2019-09-30 | 2022-08-10 | Janssen Pharmaceutica NV | Radiolabelled mgl pet ligands |
KR20220157999A (en) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | monoacylglycerol lipase modulator |
WO2022062991A1 (en) * | 2020-09-22 | 2022-03-31 | 苏州恩华生物医药科技有限公司 | Indole derivatives and use thereof |
WO2023198199A1 (en) * | 2022-04-15 | 2023-10-19 | 先声再明医药有限公司 | Myt1 kinase inhibitor |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2557342A1 (en) * | 1975-12-19 | 1977-06-30 | Hoechst Ag | BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION |
DE2931323A1 (en) * | 1979-08-02 | 1981-02-26 | Kali Chemie Pharma Gmbh | NEW N-AMINOALKYLINDOL DERIVATIVES AND THEIR SALTS |
DE3131527A1 (en) * | 1981-08-08 | 1983-02-24 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 1-PHENYL-2-AMINOCARBONYLINDOL COMPOUNDS AND METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US5023265A (en) * | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
TW229140B (en) * | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
US5424329A (en) * | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
CZ298827B6 (en) * | 1997-12-24 | 2008-02-20 | Sanofi - Aventis Deutschland GmbH | IIndole derivatives as inhibitors of Xa factor, process of their preparation and pharmaceutical composition in which they are comprised |
CZ20013608A3 (en) * | 1999-04-09 | 2002-05-15 | Astrazeneca Ab | Adamantane derivatives |
JP2003511378A (en) * | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | Triazine kinase inhibitors |
JP2004502642A (en) * | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | Cannabinoid receptor modulators, methods for their production, and use of cannabinoid receptor modulators for the treatment of respiratory and non-respiratory diseases |
US7112594B2 (en) * | 2000-08-09 | 2006-09-26 | Mitsubishi Pharma Corporation | Fused bicyclic amide compounds and medicinal use thereof |
CA2457468A1 (en) * | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient |
EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
AU2003270285B2 (en) * | 2002-10-03 | 2007-04-26 | F. Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (GK) activators |
DE10253426B4 (en) * | 2002-11-15 | 2005-09-22 | Elbion Ag | Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and methods for their preparation |
CA2510811A1 (en) * | 2002-12-20 | 2004-07-08 | Bayer Healthcare Ag | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |
FR2857966A1 (en) * | 2003-07-24 | 2005-01-28 | Aventis Pharma Sa | New piperazine and tetrahydropyridine derivatives are tubulin polymerization inhibitors used for treating cancer and disaggregating cell masses derived from vascular tissue |
SE0302192D0 (en) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
FR2874015B1 (en) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | N- (1H-INDOLYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2880625B1 (en) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
TW200700387A (en) * | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
FR2888847B1 (en) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | N- (HETERIARYL) -1-HETEORARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION |
WO2007079239A2 (en) * | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
WO2007098214A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
-
2008
- 2008-08-11 CA CA002691512A patent/CA2691512A1/en not_active Abandoned
- 2008-08-11 CN CN200880021498A patent/CN101778850A/en active Pending
- 2008-08-11 KR KR1020097026704A patent/KR20100066422A/en not_active Application Discontinuation
- 2008-08-11 SG SG2012058533A patent/SG183699A1/en unknown
- 2008-08-11 WO PCT/US2008/072760 patent/WO2009023623A1/en active Application Filing
- 2008-08-11 BR BRPI0812594-5A patent/BRPI0812594A2/en not_active IP Right Cessation
- 2008-08-11 EP EP08797591A patent/EP2185560A4/en not_active Withdrawn
- 2008-08-11 UA UAA200913336A patent/UA99729C2/en unknown
- 2008-08-11 EA EA200971085A patent/EA020332B1/en not_active IP Right Cessation
- 2008-08-11 AU AU2008286946A patent/AU2008286946B2/en not_active Ceased
- 2008-08-11 NZ NZ582056A patent/NZ582056A/en not_active IP Right Cessation
- 2008-08-11 JP JP2010520343A patent/JP2010535816A/en not_active Ceased
-
2009
- 2009-12-06 IL IL202550A patent/IL202550A0/en unknown
- 2009-12-22 CO CO09146587A patent/CO6251319A2/en not_active Application Discontinuation
-
2014
- 2014-11-25 JP JP2014238138A patent/JP2015110566A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN101778850A (en) | 2010-07-14 |
KR20100066422A (en) | 2010-06-17 |
JP2015110566A (en) | 2015-06-18 |
NZ582056A (en) | 2012-08-31 |
JP2010535816A (en) | 2010-11-25 |
CO6251319A2 (en) | 2011-02-21 |
EP2185560A4 (en) | 2011-10-05 |
AU2008286946A1 (en) | 2009-02-19 |
BRPI0812594A2 (en) | 2015-06-23 |
AU2008286946B2 (en) | 2013-11-21 |
EP2185560A1 (en) | 2010-05-19 |
EA200971085A1 (en) | 2010-06-30 |
EA020332B1 (en) | 2014-10-30 |
WO2009023623A1 (en) | 2009-02-19 |
IL202550A0 (en) | 2010-06-30 |
CA2691512A1 (en) | 2009-02-19 |
SG183699A1 (en) | 2012-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA99729C2 (en) | Heteroaryl amide analogues | |
WO2009108551A3 (en) | Heteroaryl amide analogues | |
WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
MY156288A (en) | Pharmaceutical formulations containing dopamine receptor ligands. | |
EP2119476A3 (en) | Amide derivatives as positive allosteric modulators and methods of use thereof | |
MY172926A (en) | Tetrahydropyrazolopyrimidine compounds | |
MX2015009591A (en) | Amides as modulators of sodium channels. | |
MX2009005462A (en) | 7,8-saturated-4,5-epoxy-morphinanium analogs. | |
MX2015003653A (en) | Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators. | |
WO2014120808A8 (en) | Pyridone amides as modulators of sodium channels | |
MX2010008714A (en) | Amide derivatives as positive allosteric modulators and methods of use thereof. | |
MY148657A (en) | Trpv1 antagonists and uses thereof | |
IL225198A (en) | Aminotetrahydropyran compounds, pharmaceutical compositions comprising the same and the use thereof for the treatment of diabetes | |
UA108105C2 (en) | Nitrogen-containing heteroaryl compounds | |
MX342423B (en) | 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients. | |
MY162146A (en) | Pharmaceutical composition | |
MX2011008450A (en) | Agonists and antagonists of the s1p5 receptor, and methods of uses thereof. | |
MX2013007622A (en) | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease. | |
SI2024368T1 (en) | 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain | |
WO2009120919A3 (en) | Fenofibrate dosage forms | |
TN2012000059A1 (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
UA116894C2 (en) | Novel pyrazine derivatives as cb2 receptor agonists | |
GB2477256A (en) | Medicament and method of diagnosis | |
MY148732A (en) | Triazolium salts as par1 inhibitors, production thereof, and use as medicaments | |
IT1392547B1 (en) | DEVICE FOR THE INFUSION OF DRUGS |